Roggwil, January 2, 2022 – According to an analysis of case reports and cross-sectional studies by the International Journal of Audiology, 15% of patients complain of tinnitus or worsening of their pre-infection tinnitus after a COVID-19 infection. Further consequences can be vertigo and vertigo attacks. These symptoms are believed to be caused by inflammation in the inner ear caused by the virus.
Resaphene itself has observed a significant increase in inquiries about its tinniwell from month to month since the beginning of the pandemic. As of today, there were 289 million infections worldwide, which creates an additional patient volume of 43.35 million. Resaphene Suisse AG is currently expanding its production capacities to meet the explosive growth in demand.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668